The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem therapeutics; Autem Therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Incyte (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)
 
Jun Zhang
Consulting or Advisory Role - AstraZeneca; Fosun Pharma; Novocure; Regeneron; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; MJH Life Sciences; Regeneron; Sanofi
Research Funding - Abbvie (Inst); AstraZeneca; BeiGene (Inst); Bridgebio (Inst); Champions Oncology; Genentech/Roche; Hengrui Therapeutics (Inst); Innocare (Inst); Janssen (Inst); KAHR Medical (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics; Mirati Therapeutics (Inst); Nilogen Oncosystems; Novartis (Inst); Takeda
 
Babar Bashir
Consulting or Advisory Role - Fate Therapeutics; KAHR Medical; Merck/Eisai
Research Funding - Amgen (Inst); Artios (Inst); Artios (Inst); Avenzo Therapeutics (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Lilly (Inst); Elucida Oncology (Inst); Gritstone Bio (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); KAHR Medical (Inst); Lyell Immunopharma (Inst); Merck (Inst); Pionyr (Inst); RasCal (Inst); Syros Pharmaceuticals (Inst); Tarveda Therapeutics (Inst)
 
Alexander Philipovskiy
Research Funding - Abbvie (Inst); Abbvie (Inst); Accutar Biotech (Inst); Agenus (Inst); Arvinas (Inst); Astellas Pharma (Inst); BeiGene (Inst); Frontier Med (Inst); GlaxoSmithKline (Inst); Immuneering (Inst); Inspirna (Inst); Janssen Research & Development (Inst); KAHR Medical (Inst); Loxo/Lilly (Inst); Monte Rosa Therapeutics (Inst); Valerio (Inst)
 
Robert Lentz
Consulting or Advisory Role - Agenus (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Natera (Inst)
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Experimental Drug Development Centre (EDDC)/A*STAR (Inst); Guardant Health (Inst); Lilly (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - KAHR Medical
 
Shira Amsili
Employment - KAHR Medical LTD.
Stock and Other Ownership Interests - KAHR Medical LTD.
 
Rinat Tabakman
Employment - KAHR Medical LTD.
Stock and Other Ownership Interests - KAHR Medical LTD.
 
Maria Marinova
Employment - KAHR Medical LTD.
Stock and Other Ownership Interests - KAHR Medical LTD.
 
Yaffa Shwartz
Employment - KAHR Medical LTD.
Stock and Other Ownership Interests - KAHR Medical LTD.
 
Adam Foley-Comer
Employment - KAHR Medical LTD.
Leadership - KAHR Medical LTD.
Stock and Other Ownership Interests - KAHR Medical LTD.
 
Antonio Jimeno
Stock and Other Ownership Interests - Champions Oncology; Suvica
Consulting or Advisory Role - Darkhorse consulting
Research Funding - Bristol-Myers Squibb; Flamingo Pharma; Genentech; Iovance Biotherapeutics; KHAR Medical; MediLink; Merck; Moderna Therapeutics; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Suvica; Tolerance Bio